Eli Lilly

News

Basketball great Shaq fronts Lilly sleep apnoea campaign

Eli Lilly has recruited basketball legend Shaquille O'Neal to promote a sleep apnoea awareness campaign and make the case for treatment with Zepbound.

News

Lilly wins new FDA approval for eczema drug Ebglyss

Lilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.

News

ADA: Lilly's weight-loss reveal, and wannabes display wares

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

News

White jigsaw pieces on a yellow background

Lilly strikes $1.9bn kidney disease alliance with Ascidian

In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.

News

ASCO26: Verzenio gives hope of liposarcoma treatment advance

The SARCO41 study suggests Lilly's Verzenio could become the first targeted therapy for rare, aggressive tumour dedifferentiated liposarcoma.

News

Lilly licenses Hanmi GLP-2 drug in $1.26bn deal

Eli Lilly's relentless pipeline-building drive has continued with a licensing deal for Hanmi's sonefpeglutide, in phase 2 for short bowel syndrome.

Basketball great Shaq fronts Lilly sleep apnoea campaign

Lilly wins new FDA approval for eczema drug Ebglyss

ADA: Lilly's weight-loss reveal, and wannabes display wares

Lilly strikes $1.9bn kidney disease alliance with Ascidian

ASCO26: Verzenio gives hope of liposarcoma treatment advance

Lilly licenses Hanmi GLP-2 drug in $1.26bn deal

CHMP backs Novo's haemophilia A drug Frehemgo

Discover a new era of healthcare panel engagement: Grounded ...

Eli Lilly

Editor's Picks